Verseau Therpeutics

Verseau launches with $50m to develop first-in-class macrophage-targeted immunotherapies
Pharmaceutical Business Review
Mon, 10/21/19 - 04:37 pm
Verseau Therpeutics
macrophages
immunotherapy